Last Updated on October 15, 2024 by The Health Master
New Delhi: The U.S. health regulator has approved Roche Holding AG’s therapy for treating a type of rare cancer called follicular lymphoma.
The U.S. Food and Drug Administration’s (USFDA) approval for Lunsumio was based on an early- to mid-stage study that showed the drug cleared signs of cancer in patients, with most patients responding to the treatment for at least 18 months, the company said late Thursday.
The drug, which will be available in the United States in the coming weeks, is expected to cost nearly $180,000 for a fixed course of eight cycles of treatment, the company told Reuters.
Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma, a cancer that starts in body’s white blood cells called lymphocytes.
The disease often relapses after the initial therapy and typically becomes harder to treat each time it relapses in a patient.
In the United States, about 13,000 new cases of rare cancer are estimated to be diagnosed in 2022, according to the company.
The drug, known chemically as mosunetuzumab, can be administered at a hospital’s outpatient center, unlike some other follicular lymphoma drugs that require extended hospital stays.
Roche’s drug would compete with follicular lymphoma therapies from rivals like German drugmaker Bayer AG’s Aliqopa, Novartis AG’s Kymriah, and Gilead Sciences’ Yescarta.
USFDA gives approval for Pregabalin capsules
USFDA gives approval for Brivaracetam Tablets
USFDA approves Gene Therapy for Bladder Cance
USFDA approves this lung cancer drug
USFDA gives nod for Silodosin, Pregabalin Capsules
USFDA gives final approval for Desonide cream
PCI directs State Pharmacy Councils to expedite transfer of registration of Pharmacist
300 life-saving drugs needed from Indian Pharma Cos: Saudi Arab
Registration for sale of Medical Devices: Procedure and conditions
NPPA fixes Retail Price of 10 formulations: December 2022
Drug recall: This Blood Pressure tablets recalled
Kerala to cancel licences of Medical Stores selling antibiotics without prescription
NPPA fixes Retail Price of 12 scheduled formulations: December 2022
NPPA revises Retail Price of 107 scheduled formulations: December 2022
Bulk transfer of Blood and Blood Components: Procedure and Conditions
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
